Akari Therapeutics Plc (AKTX) stock, explained like you're 5

Is Akari Therapeutics Plc a small, medium or large cap company?

No. Akari Therapeutics Plc is a micro cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 20 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Akari Therapeutics Plc makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves AKTX stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside (Stocktwits)
• Director receives conditional stock grants for unpaid retainers at Akari Therapeutics (AKTX). (Stock Titan)
• Unpaid director cash retainers are replaced by stock awards at Akari Therapeutics (AKTX). (Stock Titan)
• AKTX Stock Shoots 50% Higher To Head Toward Best Month In Nearly 11 Years What’s Fueling This Super Rally? (Yahoo Finance)
• Why Akari Therapeutics Stock Is Falling On Tuesday? (Benzinga)

Key terms to know before you follow AKTX

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility